See more : Beibu Gulf Port Co., Ltd. (000582.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Century Casinos, Inc. (CNTY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Century Casinos, Inc., a leading company in the Gambling, Resorts & Casinos industry within the Consumer Cyclical sector.
You may be interested
- Franklin BSP Lending Corporation (BDVC) Income Statement Analysis – Financial Results
- Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares (ANSC) Income Statement Analysis – Financial Results
- Touchmark Bancshares, Inc. (TMAK) Income Statement Analysis – Financial Results
- Ximen Mining Corp. (XXMMF) Income Statement Analysis – Financial Results
- Triunfo Participações e Investimentos S.A. (TPIS3.SA) Income Statement Analysis – Financial Results
Century Casinos, Inc. (CNTY)
About Century Casinos, Inc.
Century Casinos, Inc. operates as a casino entertainment company in the United States, Canada, and Poland. The company develops and operates gaming establishments, as well as related lodging, restaurant, horse racing, and entertainment facilities. As of March 8, 2022, it operated two ship-based casinos. The company was founded in 1992 and is based in Colorado Springs, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 550.21M | 430.53M | 388.51M | 304.27M | 218.23M | 168.94M | 154.07M | 139.23M | 134.43M | 120.05M | 104.59M | 71.83M | 70.87M | 60.69M | 49.74M | 53.04M | 91.65M | 56.29M | 37.45M | 40.06M | 36.06M | 29.34M | 29.58M | 29.34M | 23.60M | 19.50M | 19.70M | 11.50M | 4.20M | 3.20M |
| Cost of Revenue | 307.39M | 231.44M | 199.74M | 149.65M | 113.14M | 159.50M | 139.45M | 123.07M | 117.94M | 117.39M | 98.97M | 40.27M | 39.46M | 33.53M | 25.69M | 27.39M | 45.35M | 28.05M | 17.07M | 16.89M | 14.22M | 11.22M | 11.27M | 11.29M | 9.40M | 8.10M | 10.80M | 4.90M | 1.80M | 1.80M |
| Gross Profit | 242.81M | 199.09M | 188.77M | 154.62M | 105.09M | 9.44M | 14.62M | 16.17M | 16.49M | 2.66M | 5.62M | 31.56M | 31.41M | 27.16M | 24.05M | 25.65M | 46.30M | 28.24M | 20.38M | 23.16M | 21.84M | 18.12M | 18.31M | 18.05M | 14.20M | 11.40M | 8.90M | 6.60M | 2.40M | 1.40M |
| Gross Profit Ratio | 44.13% | 46.24% | 48.59% | 50.82% | 48.16% | 5.59% | 9.49% | 11.61% | 12.27% | 2.21% | 5.37% | 43.94% | 44.32% | 44.76% | 48.35% | 48.36% | 50.52% | 50.17% | 54.42% | 57.82% | 60.56% | 61.77% | 61.90% | 61.51% | 60.17% | 58.46% | 45.18% | 57.39% | 57.14% | 43.75% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 136.09M | 105.47M | 93.49M | 99.55M | 82.98M | 60.19M | 50.53M | 44.31M | 42.75M | 38.93M | 32.55M | 21.45M | 21.58M | 20.49M | 17.65M | 27.18M | 19.35M | 19.35M | 0.00 | 9.10M | 7.75M | 7.38M | 7.53M | 8.00M | 6.70M | 5.90M | 5.20M | 4.30M | 3.80M | 3.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.59M | 7.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 136.09M | 105.47M | 93.49M | 99.55M | 82.98M | 60.19M | 50.53M | 44.31M | 42.75M | 38.93M | 32.55M | 21.45M | 21.58M | 20.49M | 17.65M | 19.59M | 27.18M | 19.35M | 11.07M | 9.10M | 7.75M | 7.38M | 7.53M | 8.00M | 6.70M | 5.90M | 5.20M | 4.30M | 3.80M | 3.70M |
| Other Expenses | 42.67M | 260.70M | 226.50M | 204.85M | 140.47M | -3.54M | 8.95M | 8.35M | 8.00M | 7.84M | 6.60M | 4.76M | 5.56M | 6.13M | 6.14M | 34.91M | 8.10M | 24.99M | 14.53M | 7.05M | 7.29M | 3.45M | -12.59M | 3.84M | 3.50M | 3.10M | 2.90M | 2.00M | 1.30M | 900.00K |
| Operating Expenses | 178.77M | 366.17M | 319.99M | 304.40M | 223.45M | 159.50M | 139.45M | 123.07M | 117.94M | 117.39M | 98.97M | 26.21M | 27.14M | 26.62M | 23.79M | 34.91M | 35.28M | 24.99M | 14.53M | 16.15M | 15.04M | 10.83M | -5.06M | 11.85M | 10.20M | 9.00M | 8.10M | 6.30M | 5.10M | 4.60M |
| Cost & Expenses | 486.16M | 366.17M | 319.99M | 304.40M | 223.45M | 159.50M | 139.45M | 123.07M | 117.94M | 117.39M | 98.97M | 66.48M | 66.60M | 60.15M | 49.48M | 62.30M | 80.63M | 53.04M | 31.60M | 33.05M | 29.26M | 22.05M | 6.21M | 23.14M | 19.60M | 17.10M | 18.90M | 11.20M | 6.90M | 6.40M |
| Interest Income | 2.11M | 851.00K | 174.00K | 6.00K | 21.00K | 103.00K | 92.00K | 72.00K | 38.00K | 81.00K | 73.00K | 37.00K | 38.00K | 50.00K | 50.00K | 31.00K | 975.00K | 896.00K | 476.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 93.93M | 65.83M | 42.83M | 43.10M | 8.25M | 4.22M | 3.66M | 3.16M | 3.32M | 2.84M | 983.00K | 670.00K | 802.00K | 1.17M | 3.77M | 4.13M | 7.03M | 3.41M | 2.11M | 1.59M | 2.01M | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 45.27M | 31.11M | 30.80M | 30.20M | 16.75M | 9.40M | 8.95M | 8.35M | 8.00M | 7.84M | 6.60M | 4.76M | 6.14M | 6.13M | 6.14M | 9.08M | 9.99M | 5.32M | 3.80M | 3.07M | 2.78M | 2.40M | 4.65M | 3.84M | 3.50M | 3.10M | 2.90M | 2.00M | 1.30M | 900.00K |
| EBITDA | 115.36M | 102.95M | 101.78M | 30.01M | 13.74M | 18.84M | 23.56M | 24.67M | 20.43M | 10.59M | 12.22M | 10.55M | 10.63M | 8.59M | -2.17M | -585.00K | 12.20M | 3.25M | 9.64M | 7.01M | 9.61M | 9.69M | 27.95M | 9.71M | 7.48M | 5.36M | 3.50M | 2.30M | -1.40M | -2.30M |
| EBITDA Ratio | 20.97% | 14.95% | 17.64% | -0.04% | -2.39% | 5.59% | 9.49% | 11.61% | 12.30% | 2.28% | 5.31% | 14.72% | 14.75% | 11.95% | 13.68% | 18.14% | 22.01% | 6.69% | 26.21% | 35.00% | 36.98% | 42.82% | 101.45% | 35.42% | 32.20% | 24.62% | 23.35% | 33.04% | -116.67% | -75.00% |
| Operating Income | 64.05M | 33.25M | 37.72M | -149.78M | -118.36M | 9.46M | 14.62M | 16.17M | 16.49M | 2.66M | 5.48M | 5.78M | 4.27M | 1.07M | -8.73M | -9.26M | 11.03M | 3.25M | 5.85M | 7.01M | 6.80M | 7.29M | 23.36M | 6.20M | 4.00M | 2.40M | 800.00K | 300.00K | -2.70M | -3.20M |
| Operating Income Ratio | 11.64% | 7.72% | 9.71% | -49.23% | -54.24% | 5.60% | 9.49% | 11.61% | 12.27% | 2.21% | 5.24% | 8.04% | 6.02% | 1.76% | -17.55% | -17.45% | 12.03% | 5.77% | 15.61% | 17.50% | 18.87% | 24.85% | 78.99% | 21.14% | 16.95% | 12.31% | 4.06% | 2.61% | -64.29% | -100.00% |
| Total Other Income/Expenses | -87.88M | -61.60M | -40.37M | -43.16M | -6.75M | -3.54M | -2.16M | -565.00K | -1.15M | -2.24M | 1.89M | -657.00K | -577.00K | 225.00K | -3.71M | -4.54M | 3.65M | 3.19M | -1.81M | -1.42M | -1.81M | -1.76M | -19.08M | -78.00K | -84.00K | -259.00K | -900.00K | -1.50M | 3.60M | 100.00K |
| Income Before Tax | -23.83M | 6.01M | 28.15M | -43.29M | -11.97M | 5.92M | 12.45M | 15.60M | 15.34M | 418.00K | 7.37M | 5.12M | 3.69M | 1.29M | -12.08M | -13.80M | 5.85M | 6.44M | 4.04M | 5.59M | 5.02M | 5.53M | 4.22M | 5.80M | 3.90M | 2.00M | -300.00K | -1.20M | 900.00K | -3.10M |
| Income Before Tax Ratio | -4.33% | 1.40% | 7.25% | -14.23% | -5.48% | 3.51% | 8.08% | 11.20% | 11.41% | 0.35% | 7.05% | 7.13% | 5.20% | 2.13% | -24.28% | -26.01% | 6.39% | 11.44% | 10.79% | 13.94% | 13.93% | 18.86% | 14.26% | 19.75% | 16.53% | 10.26% | -1.52% | -10.43% | 21.43% | -96.88% |
| Income Tax Expense | -5.34M | -7.66M | 6.37M | 4.85M | 4.17M | 1.92M | 4.56M | 1.79M | 1.84M | 1.51M | 1.29M | 1.03M | 667.00K | 270.00K | 825.00K | 4.06M | 273.00K | 134.00K | 347.00K | 749.00K | 1.78M | 2.45M | 1.79M | 2.54M | 1.70M | 100.00K | 100.00K | 1.60M | 300.00K | -100.00K |
| Net Income | -28.20M | 13.67M | 20.62M | -48.14M | -16.14M | 3.39M | 6.26M | 9.22M | 11.91M | 1.23M | 6.18M | 4.09M | 3.02M | 1.02M | 10.88M | -13.47M | 5.33M | 7.77M | 4.48M | 4.74M | 3.25M | 3.08M | 2.46M | 3.25M | 2.20M | 1.90M | -600.00K | -1.30M | 600.00K | -3.10M |
| Net Income Ratio | -5.12% | 3.18% | 5.31% | -15.82% | -7.40% | 2.01% | 4.06% | 6.62% | 8.86% | 1.03% | 5.91% | 5.70% | 4.26% | 1.68% | 21.88% | -25.40% | 5.81% | 13.80% | 11.97% | 11.83% | 9.00% | 10.50% | 8.30% | 11.09% | 9.32% | 9.74% | -3.05% | -11.30% | 14.29% | -96.88% |
| EPS | -0.93 | 0.46 | 0.70 | -1.63 | -0.55 | 0.12 | 0.25 | 0.38 | 0.49 | 0.05 | 0.26 | 0.17 | 0.13 | 0.04 | 0.46 | -0.57 | 0.21 | 0.33 | 0.28 | 0.35 | 0.24 | 0.23 | 0.18 | 0.23 | 0.15 | 0.13 | -0.03 | -0.09 | 0.06 | -0.38 |
| EPS Diluted | -0.93 | 0.43 | 0.66 | -1.63 | -0.55 | 0.11 | 0.24 | 0.37 | 0.49 | 0.05 | 0.26 | 0.17 | 0.13 | 0.04 | 0.46 | -0.57 | 0.21 | 0.32 | 0.25 | 0.30 | 0.22 | 0.20 | 0.16 | 0.22 | 0.15 | 0.13 | -0.03 | -0.09 | 0.06 | -0.38 |
| Weighted Avg Shares Out | 30.27M | 29.81M | 29.59M | 29.56M | 29.45M | 29.40M | 25.07M | 24.44M | 24.43M | 24.38M | 24.05M | 24.00M | 23.89M | 23.61M | 23.58M | 23.46M | 23.09M | 23.12M | 16.00M | 13.54M | 13.53M | 13.39M | 13.64M | 14.14M | 14.67M | 14.62M | 20.00M | 13.90M | 10.00M | 8.16M |
| Weighted Avg Shares Out (Dil) | 30.27M | 31.48M | 31.39M | 29.56M | 29.45M | 29.96M | 25.56M | 24.67M | 24.47M | 24.42M | 24.21M | 24.11M | 24.07M | 23.80M | 23.58M | 23.46M | 23.89M | 23.84M | 17.92M | 15.79M | 14.75M | 15.40M | 15.34M | 14.79M | 14.67M | 14.62M | 20.00M | 13.90M | 10.00M | 8.16M |
Century Casinos Sees 'Green Shoots Across Several Areas Within Its Business,' Says Bullish Analyst
Century Casinos, Inc. CNTY shares continued an upward trajectory Tuesday, after climbing around 65% over the past month.
Century Casinos, Inc. (CNTY) Q3 2024 Earnings Call Transcript
Century Casinos, Inc. (NASDAQ:CNTY ) Q3 2024 Earnings Conference Call November 4, 2024 10:00 AM ET Company Participants Peter Hoetzinger - Co-Chief Executive Officer & President Erwin Haitzmann - Co-Chief Executive Officer Conference Call Participants Jordan Bender - Citizens JMP...
Century Casinos (CNTY) Reports Q3 Loss, Lags Revenue Estimates
Century Casinos (CNTY) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.47 per share a year ago.
Century Casinos Announces Opening of Century Casino & Hotel Caruthersville, MO
COLORADO SPRINGS, Colo. , Nov. 1, 2024 /PRNewswire/ -- Century Casinos, Inc. (the "Company") (Nasdaq Capital Market®: CNTY) announced today that it opened its new land-based casino and hotel in Caruthersville, Missouri.
Century Casinos Announces Opening Date for New Land-Based Century Casino & Hotel Caruthersville, MO
COLORADO SPRINGS, Colo. , Oct. 23, 2024 /PRNewswire/ -- Century Casinos , Inc. (the "Company") (Nasdaq Capital Market®: CNTY) announced today that its new land-based casino and hotel in Caruthersville, Missouri will open on November 1, 2024.
Century Casinos, Inc. (CNTY) Q2 2024 Earnings Call Transcript
Century Casinos, Inc. (NASDAQ:CNTY ) Q2 2024 Earnings Conference Call August 8, 2024 10:00 AM ET Company Participants Peter Hoetzinger - Co-CEO & President Erwin Haitzmann - Co-CEO Conference Call Participants Jeffrey Stantial – Stifel Financial Corp. Chad Beynon -...
Century Casinos (CNTY) Reports Q2 Loss, Lags Revenue Estimates
Century Casinos (CNTY) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.06 per share a year ago.
Century Casinos Announces Dates of Second Quarter 2024 Earnings Release and Conference Call
COLORADO SPRINGS, Colo. , July 31, 2024 /PRNewswire/ -- Century Casinos, Inc. (Nasdaq Capital Market®: CNTY) announced today that the Company will release its earnings for the second quarter of 2024 on Thursday, August 8, 2024.
3 Budget-Friendly Stocks With Millionaire-Making Potential
Investors with a high tolerance for risk looking for huge returns often find budget-friendly stocks to be a great option. While low-valued stocks often have a bad reputation due to their accompanying risk, it's important to find some gems with...
Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101
Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11...
Source: https://incomestatements.info
Category: Stock Reports